Gastric Cancer Clinical Trial
Official title:
Analysis of Sarcopenia and Body Composition in Relation to Outcome in a Cohort of Patients With Esophageal Cancer or Cancer of the Gastroesophageal Junction Before and After Surgery With Curative Intent
NCT number | NCT03032224 |
Other study ID # | janpe4 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 23, 2015 |
Est. completion date | July 23, 2020 |
Verified date | July 2020 |
Source | Vastra Gotaland Region |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The occurrence of dysphagia is a well-known early feature of esophageal cancer that may
reduce caloric intake and thus cause weight loss. Sarcopenia is considered to be a
consequence of such involuntary nutritional restriction. The prevalence of sarcopenia in
patients with esophageal cancer before and after surgery is not well known and its possible
consequences have been debated.
Aim: The aim of this study was to prospectively explore body composition and function in a
cohort of patients with esophageal cancer before and after surgery with curative intent. In
particular, to investigate the prevalence and development of sarcopenia and body composition
as a consequence to surgery for esophageal cancer and the possible relation to morbidity,
length of stay and quality of life (QoL).
Methods: In a cohort of 76 patients who had esophageal- or cardia-cancer and were planned for
surgery with a curative intent, data on body-composition measured with bioimpedance, working
capacity (cardiac stress test), grip strength and QoL (European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 version 3.0) were
prospectively collected. Data regarding dysphagia was derived from an esophagus related
quality of life form (EORTC QLQ-OES18). Data on tumour stage and type, complications, length
of stay and preoperative weight loss were collected from medical charts.
Status | Completed |
Enrollment | 76 |
Est. completion date | July 23, 2020 |
Est. primary completion date | July 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Cancer of the gastro-esophageal junction or the esophagus. - Planned for curative surgery. - Informed consent Exclusion Criteria: - Not fulfilling the above. - Patient declined participation. |
Country | Name | City | State |
---|---|---|---|
Sweden | Surgical Department, Sahlgrenska University Hospital | Gothenburg | Västra Götalandsregionen |
Lead Sponsor | Collaborator |
---|---|
Vastra Gotaland Region | Sahlgrenska University Hospital, Sweden, The Göteborg Medical Society, Sweden |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Body mass index (BMI) kg/m2 | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent | Weight kg | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Fat free mass (FFM) kg; | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Fat mass (FM) kg; | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Lean tissue mass (LTM) kg; | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Total body water (TBW) l; | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Intra cellular water (ICW) l; | Three months | |
Primary | Changes in Body composition after surgery for esophageal cancer with curative intent. | Extra cellular water (ECW) l | Three months | |
Secondary | Changes in QoL (linear scale 0-100) | From surgery up to three months | ||
Secondary | Changes in dysphagia (linear scale 0-100) | From surgery up to three months | ||
Secondary | Length of stay (days) | From surgery up to three months | ||
Secondary | Complications after surgery (Clavien-Dindo scale 0-5) | From surgery up to three months | ||
Secondary | Mortality | Length of survival after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |